NovotiQ

About NovotiQ

NovotiQ focuses its business interest on the development and commercialization of patent protected nasal sprays, using existing compounds only. The company will develop IP rights internally, or acquire these rights from external parties. Subsequently it will conduct the necessary clinical studies to obtain marketing authorization. Hereafter the concepts will be out-licensed/sold to the appropriate pharmaceutical parties, for commercialization. NovotiQ will bring together a (changing) group of external experts around a concept, to minimize lead times.

About the speaker
Rene van der Linden is active in the life science industry for nearly two decades. During this period he has developed expertise in commercializing research and development concepts and products. Rene has worked for companies, like SmithKline Beecham (now GlaxoSmithKline), Organon (now Merck), Pantarhei Bioscience, Middenduin Life Sciences and BioMedbooster, in several roles, e.g. product manager for the Benelux, marketing manager in France, licensing manager and business development manager and as CEO. Rene is the founder and CEO of NovotiQ. He holds a Pharm.D and a degree in Business Economics.